Skip to main content

Single-Cell Multi-Omics Market is predicted to grow at a CAGR of 21.16% during the forecast period, 2020-2025

 The single-cell multi-omics market has been evolving mainly due to the technological advancements taking place in clinical research, especially in the oncology segment. Although a growing market, the consistent evolution of technology within the market to intensify initiatives undertaken to ease diagnosis and treatment initiation have greatly adhered the market to high dynamicity. Rapid technological developments and their simultaneous adoption among major companies have made the single-cell multi-omics one of the most lucrative markets within the precision diagnostic biosphere. With both established as well as emerging players, disruptive companies playing a highly significant role in the market, this industry is rapidly evolving to regularize single-cell multi-omics in clinical as well as non-clinical applications.

The single-cell multi-omics market is estimated at $1,221.5 million in 2020 and is expected to grow at a CAGR of 21.16% during the forecast period, 2020-2025.Factors responsible for the growth of the market include increasing number of large-scale genomics studies leveraging single-cell RNA sequencing (sc-RNA), increasing adoption of personalized medicine for the screening and diagnostics of genetic disorders, and    increasing disposable income in emerging economies.

Applications for which single-cell multi-omics can be used include clinical research, translational research, and synthetic biology.End-user industries for single-cell multi-omics market include academic and research institutions, biopharmaceutical and biotechnological companies, contract research organizations, and other end users.Some of the key companies operating in the market include NanoString Technologies, Inc., RareCyte, Inc., Fluidigm Corporation, 10x Genomics, Inc., Becton, Dickinson and Company, Thermo Fisher Sciences, Fluxion Biosciences, Bio-Rad Laboratories, Inc., Namocell, Inc., 1Cell Bio, Inc., Mission Bio, Berkeley Lights, Takara Bio, Inc., Dolomite Bio, and Bio-Techne Corporation.

Growth Drivers

•    Increasing number of Large-Scale Genomics Studies Leveraging Single-Cell RNA Sequencing (sc-RNA)

•    Increasing Adoption of Personalized Medicine for the Screening and Diagnostics of Genetic Disorders

•    Increasing Disposable Income in Emerging Economies


Market Restraints

•    High Cost of Single-Cell Analysis and Integration of Data

•    Limited Availability of Large Online Data Storage and Analysis Platforms


Market Opportunities

•    Massive Scope for Adoption of Genomic-Based Medicine in Emerging Nations

•    Requirement for the Development of Advanced Solutions Based on Single-Cell Technology

•    Increased Use of Single-Cell Technology Solutions for the Development of Therapeutics Drugs and Comprehensive Treatment Plan

•    Expansion into New Research Application such as Single-Cell Metabolomics

Within the research report, the market is segmented on the basis of product type, sample type, omics type, technique, application, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Request a Sample- https://bisresearch.com/requestsample?id=1061&type=download

Labels:

Comments

Post a Comment

Popular posts from this blog

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

  Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing   microbiome therapeutics market    is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...
Post a Comment
Read more

Ligase Market Opportunities, Strategies, Share, Segmentation, In-depth Analysis 2032

  The global ligase market is progressing rapidly with a significant increase in the research and development activities pertaining to a wide range of ligase product for disease detection, accentuating their criticality in healthcare. Ligase enzyme has a critical role in the molecular diagnostics approach, as it ensures the safe and effective application of targeted therapeutics. Most of the players in the global ligase market offer products encompassing the ligation kits and enzymes. The global  ligase market  is projected to reach $651.4 million by 2032 from $371.2 million in 2021, at a CAGR of 5.29% during the forecast period 2022-2032. The growth in the global ligase market is expected to be driven by factors such as the increasing prevalence of infectious and genetic diseases on a global level, rising awareness of enzyme based diagnostic testing and significant number of funding for executing research and development.   Impact Several techniques are employed in ...
Post a Comment
Read more

PD-1/PDL-1 Inhibitor Market Growth Prospects, Emerging Trends and Forecast to 2032

  PD-1/PDL-1 inhibitors are immune-therapeutic agents used in the treatment of various cancer indications, mostly in the advanced stages. PD-1/PDL-1 inhibitors are monoclonal antibodies majorly of IgG1 and IgG4 types to be administered to patients via injection The current market already has seven approved products in the U.S. and a large number of research activities are currently undergoing in this segment generating interest of commercial as well as academic research institutions. In the current period of precision medicine and providing targeted treatment, identification of target patient has become very important as well as complicated. With the emergence of diagnostic test identifying predictive biomarkers, the selection and administration of targeted treatment has become comparativlely conveninent and efficient. PD-1/PDL-1 inhibitors market   are majorly indicated for the treatment of advanced cases of different cancer indications. The PD-1/PDL-1 inibitor treatment has ...
Post a Comment
Read more